Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 545 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Thank you! March 22, 2021 Lung-Sparing Surgery Is Effective for Some with Early-Stage Lung Cancer March 9, 2023 Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... March 11, 2024 Blood test could tailor treatment after surgery July 14, 2021 Load more HOT NEWS Dexrazoxane Protects the Heart Long Term for Kids Being Treated for... In memory of Dame Deborah James EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer...
